Yinlian Wu

Yinlian Wu

Auto-generated profile, based on publicly available information

Yinlian Wu

Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
QZQianwen Zhao
Qianwen Zhao
MMMeng Meng
Meng Meng
RKRahul Kumar
Rahul Kumar
YWYinlian Wu
Yinlian Wu
JHJiaofeng Huang
Jiaofeng Huang
SLSu Lin
Su Lin

1 October 2016 in Medicine
Verified
Journal Article
Open access
YWYinlian Wu
Yinlian Wu
MWMingfang Wang
Mingfang Wang
YZYueyong Zhu
Yueyong Zhu
SLSu Lin
Su Lin
The diagnostic accuracy of interleukin-6 (IL-6) in predicting bacterial infection in cirrhotic patients remains unclear. The aim of this meta-analysis is to explore the potential diagnostic value of IL-6 in cirrhotic patients. We systematically searched PubMed, Embase (via OvidSP), Web of Science, the Cochrane Library, and Scopus for studies published from inception to October 2015. Studies were enrolled if they included assessment of the accuracy of IL-6 in the diagnosis of bacterial infection in cirrhotic patients and provided sufficient data to construct a 2 × 2 contingency table. Totally, 535 studies were searched in the initial database and finally 6 studies involving 741 patients were included for the final analysis. The pooled sensitivity, specificity and diagnostic odds ratio were 0.85 (95% confidence interval [CI], 0.64–0.94), 0.91 (95% CI, 0.80–0.96) and 52.89 (95% CI, 15.21–183.86), respectively. The pooled positive likelihood ratio was 8.99 (95% CI, 4.13–19.55) and the pooled negative likelihood ratio was 0.17 (95% CI, 0.07–0.43). The area under the receiver operating characteristic curve was 0.94 (95% CI, 0.92–0.96). This meta-analysis suggests IL-6 has a high diagnostic value for the differentiation of bacterial infection in patients with cirrhosis.

12 January 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
XCXiaoning Chen
Xiaoning Chen
GGGeorge Boon Bee Goh
George Boon Bee Goh
JHJiaofeng Huang
Jiaofeng Huang
YWYinlian Wu
Yinlian Wu
MWMingfang Wang
Mingfang Wang
YZYueyong Zhu
Yueyong Zhu
Metabolic-associated fatty liver disease (MAFLD) is a newly proposed terminology from 2020; yet, the applicability of conventional noninvasive fibrosis models is still unknown for it. We aimed to evaluate the performance of conventional noninvasive fibrosis scores in MAFLD.

1 July 2021 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
JHJiaofeng Huang
Jiaofeng Huang
WXWenjuan Xue
Wenjuan Xue
MWMingfang Wang
Mingfang Wang
YWYinlian Wu
Yinlian Wu
MSMedha Singh
Medha Singh
SLSu Lin
Su Lin
Introduction: Metabolic associated fatty liver disease (MAFLD) is a novel concept for fatty liver disease. Different from non-alcoholic fatty liver disease (NAFLD), the diagnosis of MAFLD requires the presence of metabolic risks. This study aimed to characterize patients with liver steatosis but without metabolic risks (non-MR-steatosis) which may not be diagnosed by MAFLD criteria. Methods: Consecutive patients who underwent biopsy were included in this study. The clinic-pathological characteristics of non-MR-steatosis, NAFLD and MAFLD were compared. Results: A total of 1217 cases were included. There were 426 (35.00%) cases with MAFLD, 585 (48.07%) with NAFLD and 168 (13.80%) with non-MR-steatosis. The majority of the cases were infected with HBV (93.26%). The age and metabolic profiles were highest in MAFLD and lowest in non-MR-steatosis. The body mass index (BMI) level was also lowest in non-MR-steatosis (20.78 ± 1.54 kg/m2). The ALT and AST levels of the non-MR-steatosis group were not statistically different from those of MAFLD or NAFLD groups (p > 0.05). Histologically, there was no significant difference in the degrees of inflammation and fibrosis among the three groups. The severity of steatosis in non-MR-steatosis group was lower than MAFLD or NAFLD groups (p < 0.05). These results were consistent in both HBV and non-HBV subgroups. Conclusion: MAFLD criteria may overlook some steatotic patients without metabolic risks, who may also have steatohepatitis and significant fibrosis.